ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Sodium Chloride → (R)-tert-butyl 3-(1-(3-(pyridin-4-yl)-1-trityl-1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate

HRID 1465686
ノート
印刷プレビュー

反応式

HRID 1465686 の反応式
[N:1]([C:4]1[CH:5]=[C:6]2[C:10](=[CH:11][CH:12]=1)[N:9]([C:13]([C:26]1[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1)([C:20]1[CH:25]=[CH:24][CH:23]=[CH:22][CH:21]=1)[C:14]1[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=1)[N:8]=[C:7]2[C:32]1[CH:37]=[CH:36][N:35]=[CH:34][CH:33]=1)=[N+:2]=[N-:3].[C:38]([C@@H:40]1[CH2:45][CH2:44][CH2:43][N:42]([C:46]([O:48][C:49]([CH3:52])([CH3:51])[CH3:50])=[O:47])[CH2:41]1)#[CH:39].[Na+].[Cl-]>CC(O)(C)C.O>[N:35]1[CH:34]=[CH:33][C:32]([C:7]2[C:6]3[C:10](=[CH:11][CH:12]=[C:4]([N:1]4[CH:39]=[C:38]([C@@H:40]5[CH2:45][CH2:44][CH2:43][N:42]([C:46]([O:48][C:49]([CH3:52])([CH3:51])[CH3:50])=[O:47])[CH2:41]5)[N:3]=[N:2]4)[CH:5]=3)[N:9]([C:13]([C:20]3[CH:25]=[CH:24][CH:23]=[CH:22][CH:21]=3)([C:26]3[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=3)[C:14]3[CH:15]=[CH:16][CH:17]=[CH:18][CH:19]=3)[N:8]=2)=[CH:37][CH:36]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 5234Sodium ChlorideHCID 52420760tert-butyl (3S)-3-ethynylpiperidine-1-carboxylateHCID 866955715-azido-3-(pyridin-4-yl)-1-trityl-1H-indazole

生成物 1

HCID 67517916(R)-tert-butyl 3-(1-(3-(pyridin-4-yl)-1-trityl-1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate収率 87.2%

試薬・触媒・溶媒 1

HCID 71401949
2-Methylpropan-2-ol--water (1/1)
溶媒

実験手順

5-azido-3-(pyridin-4-yl)-1-trityl-1H-indazole (1.0 g, 2.1 mmol) and (S)-tert-butyl 3-ethynylpiperidine-1-carboxylate (0.43 g, 2.1 mmol) were suspended in t-BuOH:H2O (1:1 10 mL:10 mL) and then CuSO4.5H2O (5 mg, 0.002 mmol) and Na-Ascorbic acid (40 mg, 0.21 mmol) were added sequentially. Reaction mixture was stirred vigorously at room temperature overnight. After the completion of reaction, added sat. NaCl (30 mL), extracted with EtOAc (3×50 mL), evaporated the organic solvent to give (R)-tert-butyl 3-(1-(3-(pyridin-4-yl)-1-trityl-1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate (1.26 g) which was used for next step with out purification.

後処理

  1. customReaction mixture
  2. customAfter the completion of reaction
  3. extractionextracted with EtOAc (3×50 mL)
  4. customevaporated the organic solvent

出典と根拠

ORDレコード
ord-9fb3fe16002e495aaad1cb4b734292ad
出典データセット
uspto-grants-2015_04
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08999966B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート